Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing 29 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development. Click on a project for further information.

 

More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.

 

Phases

Number of programs in clinical development.

 

Download
Pipeline Package
Download
Pipeline One-pager
A woman in a white shirt smiles at the camera.
Dr. Julia Schulze
Research
julia.schulze@bayer.com
Therapeutic Areas
Oncology (ONC)
Cardiovascular /
Renal (CVR)
Neurology &
Rare Diseases (NRD)
Immunology (IM)
Others
PhaseAreaProgram (Mode-of-action)Indication 
IIIONCDarolutamide
(AR Inhibitor)		Adjuvant Prostate Cancersmall molecule
IIIONCDarolutamide
(AR Inhibitor)		Prostate Cancer with
Biochemical Recurrence after
Curative Radiotherapy		small molecule
IIICVRFinerenone
(MR Antagonist)		Non-diabetic CKD
(FIND-CKD)		small molecule
IIINRDBemdaneprocel (Cell Therapy)Parkinson's Disease
(exPDite-2)		Cell Therapy_NTE
IIIOthers124I-Evuzamitide
(PET Tracer)		Diagnosis of Cardiac Amyloidosis (REVEAL)Imaging Agent
IIONCSevabertinib (HER2/mEGFR Inhibitor)Metastatic or Unresectable Solid Tumors with HER2-activating Mutations (PanSOHO)small molecule
IICVRUmiposgene ParvecCongestive Heart Failure
(GenePHIT)		gene therapy
IICVRInclocibart (Anti-a2AP)Acute Ischemic Stroke;
Pulmonary Embolism
(SIRIUS)		Protein Therapy
IICVRNurandociguat
(sGC Activator Oral)		Chronic Kidney Disease
(ALPINE-1)		small molecule
IICVRSEMA 3aAlport Syndrome (ASSESS)Protein Therapy
IINRDAmetefgene ParvecParkinson's Disease
(REGENERATE-PD)		Genetic Therapy
IIOthersEdonentan (PER-001, BAY 3826827)Non-proliferative Diabetic Retinopathysmall molecule
IIOthersEdonentan (PER-001, BAY 3826827)Glaucomasmall molecule
IONCVVD Keap1 ActAdvanced Solid Tumorssmall molecule
IONCActinium (225Ac) Felivotide MopaxetanAdvanced Prostate CancerRadiotherapy_NTE
IONCSOS1 InhibitorAdvanced Solid Cancerssmall molecule
IONCPRMT5 InhibitorMTAP-deleted Solid Tumorssmall molecule
IONCVVD RAS-PI3K InhibitorAdvanced Solid Tumorssmall molecule
IONC225Ac-GPC3Advanced Liver CancerRadiotherapy_NTE
IONCVVD WRN InhibitorAdvanced Solid Tumorssmall molecule
IONCKRAS G12D InhibitorAdvanced Solid Tumorssmall molecule
ICVRDual FIIa/Xa InhibitorAnti-coagulationsmall molecule
ICVRGIRK4 InhibitorAtrial fibrillationNew Melecular Entity
ICVRBAY 3620122Vasoplegiasmall molecule
INRDAmetefgene ParvecMultiple
System Atrophy		Gene Therapy_NTE
INRDPompe Disease
AAV Gene Therapy		Pompe DiseaseGene Therapy_NTE
INRDLGMD2I/R9
AAV Gene Therapy		Limb Girdle
Muscular Dystrophy		Gene Therapy_NTE
IOthersPrimary Photoreceptor Diseases
Cell Therapy		Primary Photoreceptor DiseaseCell Therapy_NTE
IOthersAT-05 SPECT TracerDiagnosis of Cardiac Amyloidosisimaging agent

 

A row of six medical terms, each preceded by a pink icon: Protein Therapy (helix), Cell Therapy (cell), Genetic Therapy (DNA), Radionuclide Therapy (atom symbol), Imaging Agent (vial/bottle), and Small Molecule (molecular structure).

 

New Molecular Entity   New molecular entity
Life cycle management   Life cycle management

 

Derin Denham
Derin Denham
derin.denham@bayer.com
Discover more
Bayer Cross
Creating the Future You
Proactive Ways to Get Healthier as You Get Older
How we age is a collection of a number of factors. And a lot of them are in your control. Be proactive in creating the future you.
Read More
2 min read
A laboratory technician in protective gear pours liquid into a large round-bottom flask. The image is taken from a low angle, with numerous flasks containing yellowish liquid framing the scene in the foreground.
Our engagement
Balancing act between innovative cancer medicines and generics
The Chinese government has eliminated tariffs and is reducing VAT on cancer drugs, putting more pressure on reimbursement negotiations and procurement processes to urge pharma companies to transfer this economic benefit to patients. This will put price pressure on cancer drugs, ideally without compromising on quality.
Read More
5 min read
Two laboratory technicians look intently at a small, transparent microscope slide held by the person on the left. In the bottom left corner, there is a white logo featuring the number "30" and the text "Years From Now".
OUR ENGAGEMENT
Investing in Wellness Strategies for an Actively Aging Society
Policy changes must make way for market innovation to enhance functional ability as we age, says Michael Hodin, CEO of the Global Coalition on Aging. 30 years from now, the new metric for success in healthcare will be wellness prevention and the preservation of functional ability.
Read More
4 min read
A woman's face is shown with a number of icons on it.
Our Engagement
Prevention is Within Reach With Artificial Intelligence
Data science and advanced analytics are driving the digitalization of healthcare systems. Smart, platform-based applications are designed to further improve the quality of medical care and provide personalized solutions to manage, treat and, ultimately, prevent disease.
Read More
5 min read
A woman with blond hair is holding a cell phone.
Our engagement
Redesigning the 100-Year-Life Society
The future of aging lies beyond standardization, according to Esko Aho, Chairman of the Board of Cinia Oy and Adven Group. From pharmaceuticals to service design, the shift towards personalization is raising our standard of living. Mr Aho believes that in thirty years, a good life will be controlled by individuals.
Read More
4 min read
A person is sitting on a chair with a robotic arm.
OUR ENGAGEMENT
Paving the Way for Progressive Healthcare
Japan is leading the way in healthcare research, development and delivery for its aging populations, says Dr. Michael Devoy, Chief Medical Officer for Bayer’s Pharmaceuticals Division. In thirty years, healthcare systems should focus on extending the maintenance of healthy, active lifestyles.
Read More
3 min read
Two laboratory workers wearing lab coats and safety glasses look intently at a microscope slide. The person in the foreground holds the slide with a purple-gloved hand. The entire image has a subtle reddish-purple color overlay.
Precision Oncology
Targeted and Effective Tumor Therapy
Conventional cancer therapy often comes with severe side effects. With new treatment methods, some tumors can be targeted effectively, reducing these adverse effects. Read what experts are saying about precision oncology’s potential.
Read More
6 min read
A medical technology graphic featuring a hand in a doctor's coat reaching forward in the foreground, touching a floating, three-dimensional rendering of a human heart. The heart is surrounded by a network of digital lines and medical icons (such as capsules, a stethoscope, and heart rate symbols). The entire image is layered with a slightly dimmed, reddish-purple color filter.
Heart Failure
New Compounds Give Patients Hope
The figures are alarming: One in five people will develop heart failure in the course of their lives. More than 40,000 deaths a year in Germany alone are caused by a weak heart. New therapies could offer hope in the future. They are designed to strengthen the body's most important muscle and could thus potentially improve the quality of life of those affected and reduce hospital admissions and deaths.
Read More
5 min read
A close up of a person wearing colorful glasses.
OUR ENGAGEMENT
The Long Hunt For The Next Breakthrough
Only one in 10,000 active ingredients created by researchers in a lab is turned into a potential drug. But pharmaceutical research is not only expensive and time-consuming, it’s also a process liable to lead to a dead end. How drugs make the long journey from lab to market.
Read More
6 min read
An elderly woman is holding an elderly woman's hand.
OUR ENGAGEMENT
Boosting Longevity and Prosperity in Developing Nations
Developing nations are transitioning to rapidly aging societies – and in order to support their populations, governments must invest in human capital, says Annette Dixon, Vice President for Human Development at the World Bank Group. In 30 years, people must be able to be productive and active for as long as possible.
Read More
4 min read
A digital concept graphic exploring artificial intelligence, featuring a woman's face where one half is human and the other half transitions into a white robot or android face. The human eye looks directly forward, while the robotic eye glows blue and shows mechanical details. The background is overlaid with a pattern of digital data streams, circuits, and points of light.
Transforming Healthcare. For People.
Detecting Skin Cancer in The Bathroom Mirror
The field of medicine is currently experiencing an incredible surge in innovation, driven by groundbreaking new biological discoveries, a digital revolution and a growing willingness to collaborate in research globally. What can patients expect for the future?
Read More
6 min read